MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

On August 11, 2026 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, reported that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies’ 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The licensed program incorporates MacroGenics’ TRIDENT platform and is directed against two undisclosed targets for the treatment of solid tumors. Under the 2022 collaboration agreement, MacroGenics and Gilead Sciences are advancing three programs: MGD024, a clinical-stage CD123 × CD3 bispecific DART molecule, and two preclinical bispecific programs.

MacroGenics remains eligible to receive up to approximately $1.6 billion in additional development, regulatory and commercial milestone payments across the collaboration, as well as royalties on worldwide net sales of products resulting from the programs.

(Press release, MacroGenics, AUG 11, 2026, View Source [SID1234669963])

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

On August 11, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango or the Company), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported financial results for the second quarter ended June 30, 2026, and provided business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The second quarter marked a pivotal period for Tango, with milestones that validated our PRMT5 inhibitor pipeline and reflect the progress of our maturing organization. Notably, initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate with encouraging durability in MTAP-deleted, RAS-mutant pancreatic cancer, giving us the confidence to move this combination rapidly into Phase 3 development for patients," said Malte Peters, MD, Chief Executive Officer of Tango. "As the Company transitions from a research-led organization into one positioned to bring vopimetostat to patients, our focus for the second half of the year remains on defining the registrational path for vopimetostat in front-line pancreatic cancer and providing updates from our broader pipeline. I am pleased with the progress we have made against executing on our clinical development plan, which is well on track, and the team continues to be laser-focused on bringing vopimetostat to patients as soon as possible. With our robust balance sheet, our cash runway carries us through our planned development and commercialization preparation in pancreatic cancer, as well as ongoing work across our pipeline."

Clinical Pipeline Updates

Vopimetostat – MTAP Selective Once-Daily PRMT5 Inhibitor

In June, Tango reported initial data from vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Data demonstrated that vopimetostat in combination with daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival rate in this patient population, with a generally well-tolerated safety profile.
Based upon the positive Phase 1/2 data, Tango is working internally and has initiated dialogue with regulators and its collaborator Revolution Medicines toward the goal of developing a registrational plan and path forward for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer.
The Company plans to share data from the Phase 1/2 trial of the combination of vopimetostat plus RAS(ON) inhibitors at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Madrid, Spain from October 23-27, 2026.

Corporate Updates

Executive Leadership. Today, the Company announced that it has appointed Fatma Ocak to the role of Chief Commercialization Officer, effective August 17, 2026. In this role, Ms. Ocak will oversee all aspects of launch readiness and oversee key functions, including medical affairs, commercial strategy, and clinical and commercial integration. Prior to joining Tango, she served as Senior Vice President and General Manager, US Oncology at BioNTech. Previously, she held senior executive roles at Novartis across both global and US oncology leadership, driving strategic product positioning, market access, and commercial execution. Throughout her 25-year career in pharmaceuticals, she has specialized in bridging research and development to competitive market execution.
Board of Directors. In June, the Company strengthened its Board of Directors with the appointment of Robert Azelby, adding more than 30 years of biopharmaceutical leadership experience in oncology commercialization and corporate strategy as Tango prepares to advance vopimetostat into late-stage clinical development. On August 6, 2026, Mr. Azelby was appointed Chairman of the Tango Board of Directors.

Upcoming Expected Milestones

Present Phase 1/2 data of vopimetostat in combination with RAS(ON) inhibitors at the 2026 ESMO (Free ESMO Whitepaper) Congress in Madrid, Spain from October 23-27, 2026
Finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pancreatic cancer in 2H 2026
Disclose vopimetostat lung cancer monotherapy data in 2H 2026
Release initial TNG456 data in glioblastoma and other cancers in 2H 2026
Initiate Phase 1/2 vopimetostat + ERAS-0015 (Erasca) combination study in 2H 2026

Financial Results

As of June 30, 2026, the Company held $1.0 billion in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan.

Collaboration revenue was $0 for the three months ended June 30, 2026, compared to $3.2 million for the same period in 2025, and $0 for the six months ended June 30, 2026, compared to $8.6 million for the same period in 2025. All remaining deferred revenue from the upfront and research option-extension payments under the Gilead collaboration was recognized as collaboration revenue during the year ended December 31, 2025 as a result of the truncation of the collaboration agreement which concluded all research activities.

Research and development expenses were $37.2 million for the three months ended June 30, 2026, compared to $32.8 million for the same period in 2025, and $70.7 million for the six months ended June 30, 2026, compared to $69.2 million for the same period in 2025. The change was primarily due to increased spend related to the advancement of the vopimetostat and TNG456 clinical programs. This increase was partially offset by decreased spend resulting from the impact of our portfolio prioritization efforts.

General and administrative expenses were $22.6 million for the three months ended June 30, 2026, compared to $11.3 million for the same period in 2025, and $37.8 million for the six months ended June 30, 2026, compared to $22.8 million for the same period in 2025. The increase was primarily due to increased spend on personnel-related costs, including share-based compensation expense.

Net loss for the three months ended June 30, 2026 was $55.3 million, or $0.37 per share, compared to a net loss of $38.9 million, or $0.35 per share, in the same period in 2025. Net loss for the six months ended June 30, 2026 was $100.9 million, or $0.68 per share, compared to a net loss of $78.7 million, or $0.71 per share, in the same period in 2025.

(Press release, Tango Therapeutics, AUG 11, 2026, View Source [SID1234669979])

Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

On August 11, 2026 Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Completing enrollment in our Phase 3 CoMpass trial of bel-sar for early choroidal melanoma positions us well for the next phase of our company’s evolution to become a leading ocular oncology company," said Natalie Holles, Chief Executive Officer of Aura Biosciences. "Given the promising therapeutic profile of bel-sar and the significant unmet need for a new treatment in this field, we are prioritizing our efforts and resources on delivering meaningful development milestones, providing ocular oncologists with frontline, vision-preserving treatment options for patients, and creating long-term value for shareholders."

Recent Business Highlights

Early Choroidal Melanoma

The Phase 3 CoMpass trial, the first registration-enabling study in patients with early choroidal melanoma, is fully enrolled with 108 patients, which exceeded the enrollment target. Topline data from the 15-month primary endpoint remain on track for the second half of 2027, consistent with previously communicated guidance.

The trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), reflecting alignment with the FDA on the trial design and planned analyses to support a potential Biologics License Application (BLA). If successful, belzupacap sarotalocan (bel-sar) has the potential to become the first approved frontline vision-preserving therapy for patients with early choroidal melanoma, providing a meaningful new treatment option where no FDA-approved drug therapies currently exist.

Additional Ocular Oncology Programs

Aura continues to advance the clinical development of bel-sar in metastases to the choroid and cancers of the ocular surface. The Company is increasing resources directed toward both programs to support more robust clinical data generation in support of future development. Aura expects to provide an update on both programs, including guidance on study completion, in Q1 2027.

NMIBC Program Update

Interim data from the ongoing Phase 1b/2 dose-escalation study of bel-sar in non-muscle invasive bladder cancer (NMIBC) demonstrate an encouraging early clinical profile. Among intermediate-risk patients treated with bel-sar alone (n=8) or with TURBT (n=8), 81% of patients achieved an objective response at 3 months, including 69% with a complete response at that timepoint. Responses have shown strong early durability: among evaluable patients who have reached the 9- (n=4) or 12-months (n=3) timepoints, 100% of evaluable patients remain disease-free at time of assessment. Three-month data collection is ongoing in the high-risk cohorts.

Bel-sar continues to demonstrate a favorable safety profile, with all treatment-related adverse events limited to Grade 1 events, no dose-limiting toxicities, and no treatment-related serious adverse events. These data provide encouraging early clinical proof-of-concept for intratumoral delivery of bel-sar and support the potential utility of this route of administration for ocular cancers.

While these early data are encouraging, as part of its strategic refocus on ocular oncology, the Company is minimizing resource allocation toward the NMIBC program on a going forward basis. The Company remains committed to the care of patients and intends to complete data collection through the protocol-defined 12-month follow-up period to preserve optionality for value creation in the context of future potential strategic discussions.

Organizational and Leadership Updates

Aura has streamlined its operating plan and organizational structure to focus resources in ocular oncology, including a reduction in force of approximately 20% of the workforce. Together with disciplined capital allocation, these actions are expected to extend the Company’s projected cash runway into the first half of 2029 to support execution of the Phase 3 CoMpass trial, advancement of its additional ocular oncology programs and preparation for potential commercialization.

Aura reported the appointments of Susan Abu-Absi as Chief Operating Officer, Erica Kratz as Chief Regulatory and Quality Officer, and Julie Person as Chief People Officer. As previously announced on July 8, 2026, Jeremy Bender also joined the Company’s Board of Directors.

"I am thrilled to welcome Susan, Erica and Julie to Aura," said Natalie Holles. "As we sharpen our focus on ocular oncology and advance bel-sar toward potential BLA filing, we are building a fit-for-purpose organization with the capabilities needed for our next stage of growth. Their collective experience will be invaluable as we execute on our strategy and prepare for potential registration and commercialization."

Aura also announced that Tony Gibney, Chief Financial and Business Officer and Conor Kilroy, Chief Legal Officer are stepping down, and Mark Plavsic has stepped down as Chief Technology Officer.

"On behalf of the Board and the entire Aura team, I want to thank Tony, Conor and Mark for their leadership and contributions to Aura," said Natalie Holles. "Each has played an important role in advancing the Company and positioning Aura for this next chapter, and we wish them all the very best in their future endeavors."

Susan Abu-Absi, Ph.D., Chief Operating Officer

Susan Abu-Absi, Ph.D., is a seasoned biopharmaceutical executive with more than 20 years of leadership experience spanning technical development, manufacturing, quality and global operations. Most recently, she served as Chief Operating Officer at Be Biopharma, where she led the company’s operational strategy and execution. Prior to Be Biopharma, she was Chief Technology Officer at 2seventy bio, leading technical development, supply and quality and supporting the commercialization of Abecma as well as the advancement of multiple cell therapy programs. Previously, Susan held senior leadership roles at bluebird bio, where she played an integral role in the approvals of Zynteglo and Skysona, and at Bristol Myers Squibb and Bayer Healthcare. She holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering from the University of Toledo.

Erica Kratz, Ph.D., Chief Regulatory and Quality Officer

Erica Kratz, Ph.D., is a regulatory affairs and quality executive with more than 20 years of experience leading global regulatory strategy and development quality across the biotechnology industry. Most recently, she served as Senior Vice President, Regulatory Affairs and Head of Development Quality Assurance at Denali Therapeutics, where she built and led the team from the company’s first clinical trial through the advancement of multiple programs into the clinic, including the BLA submission and FDA approval of Avlayah in Hunter Syndrome. Prior to Denali, Erica spent a decade at Genentech, where she led global regulatory strategy for multiple oncology programs spanning early development through commercialization, including U.S. and Canadian marketing applications for Herceptin in gastric cancer. She holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley and a B.S. in Cell and Molecular Biology from the University of Arizona.

Julie Person, Chief People Officer

Julie Person is a human resources executive with more than 20 years of experience leading people strategy and organizational development across the biopharmaceutical industry. Most recently, she served as Chief People Officer at Vera Therapeutics. Prior to Vera, Julie served as Chief People Officer at Third Harmonic Bio and held senior human resources leadership roles at Neumora Therapeutics, Audentes Therapeutics, Sangamo Therapeutics, Shire, Blue Shield of California and McKesson. Her experience spans organizational design, talent acquisition, leadership development, culture and change management, supporting organizations through all stages of growth from early development to commercialization. She holds a B.A. in Communications from Saint Mary’s College of California.

Second Quarter 2026 Financial Results


As of June 30, 2026, Aura had cash and cash equivalents and marketable securities totaling $323.8 million. The Company believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 1H 2029.


Research and development expenses increased to $30.7 million for the three months ended June 30, 2026 from $22.9 million for the three months ended June 30, 2025, primarily due to ongoing clinical and CRO costs associated with the progression of the CoMpass global Phase 3 trial of bel-sar in early choroidal melanoma and manufacturing and development costs for bel-sar.

General and administrative expenses increased to $17.3 million for the three months ended June 30, 2026 from $5.7 million for the three months ended June 30, 2025. General and administrative expenses include $10.3 million and $1.8 million of stock-based compensation for the three months ended June 30, 2026 and 2025, respectively. The increase was primarily driven by increased stock-based compensation expense resulting from equity award modifications in connection with executive leadership transitions, as well as higher professional fees.


Net loss for the three months ended June 30, 2026 was $45.6 million compared to $27.0 million for the three months ended June 30, 2025.


In connection with the Company’s organizational restructuring to align resources behind its ocular oncology portfolio, the Company estimates to incur restructuring charges of approximately $2.9 million to $3.2 million, comprised of employee termination benefits which include severance, continuation of health care benefits, and outplacement services as well as incremental stock-based compensation expense resulting from the acceleration of vesting of certain stock-based awards. The restructuring plan is expected to be substantially complete by the end of the third quarter of 2026.

(Press release, Aura Biosciences, AUG 11, 2026, View Source [SID1234669941])

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

On August 11, 2026 Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have successfully converted last quarter’s regulatory achievements into clinical progress in the VCN-01 program," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. "Dosing of the first patients in the VIRAGE2 trial brings us closer to refining a VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in first-line metastatic PDAC patients when coadministered with chemotherapy. A repeated VCN-01 dosing regimen may also improve outcomes when combined with other cancer interventions, including immuno-oncology products, RAS inhibitors, and other emerging classes of cancer treatments. If more frequent repeated administration of VCN-01 is feasible and well-tolerated, use of this dosing regimen may further derisk future Phase 3 clinical trials."

Recent Highlights and Anticipated Milestones

VCN-01

Metastatic PDAC:

As recently announced, the first patients have been dosed in the VIRAGE2 Phase 2a clinical trial entitled "A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial evaluating increased frequency dosing of zabilugene almadenorepvec (VCN-01) in combination with gemcitabine/nab-paclitaxel in patients with newly-diagnosed metastatic pancreatic cancer" (EUCT: 2026-525566-21-00; NCT07701486).
The VIRAGE2 study design incorporates feedback from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) recognizing improved survival outcomes in the VIRAGE Phase 2b trial in metastatic PDAC patients treated with 2 doses of VCN-01 (in combination with standard-of-care chemotherapy), highlighting the possibility that more frequent repeated dosing of VCN-01 may provide additional clinical benefit.
The VIRAGE2 trial will evaluate the safety and feasibility of administering at least 3 doses of VCN-01 given approximately 2 months apart in combination with standard-of-care chemotherapy. The trial is expected to enroll 6 evaluable patients. Results from the VIRAGE2 study will inform the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial.
VIRAGE2 is expected to complete enrollment during the second half of 2026, and initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027.
Retinoblastoma:

Undertook extensive discussions with key opinion leaders and completed the design of a proposed Phase 2/3 clinical trial of intravitreal VCN-01 in combination with intravitreal topotecan in children with retinoblastoma with vitreous seeds that are refractory/resistant to the use of current intravitreal chemotherapy.
Proposed clinical trial protocol builds on compelling Phase 1 clinical data in this ultra rare population for which there is no current treatment.
Plan to discuss the proposed clinical trial protocol with the FDA in Q3 2026.
VCN-01 has Orphan Drug Designation from both the FDA and EMA and Rare Pediatric Disease Designation from the FDA for the treatment of retinoblastoma; if a Biologics License Application (BLA) for VCN-01 for the treatment of retinoblastoma is approved by the FDA by September 30, 2029, the Company may be eligible to receive a Priority Review Voucher.
Head & Neck Squamous Cell Carcinoma:

Clinical and translational results from the Phase 1 clinical trial of VCN-01 in refractory or metastatic head & neck squamous cell carcinoma (HNSCC) patients (whose disease progressed despite previous therapies, including anti-PD-(L)1 immune checkpoint inhibitors) were published in the journal Clinical Cancer Research in an online first article titled "Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy".
In the Phase 1 trial, prolonged overall survival (OS) was observed in these heavily pre-treated refractory HNSCC patients administered intravenous VCN-01 prior to the immune checkpoint inhibitor durvalumab (sequential delivery).
Pharmacokinetic, tissue biopsy, radiomic and transcriptomic results all support the proposed VCN-01 stroma-degrading and immune enhancing modes-of-action, resensitizing refractory tumors to durvalumab.
These findings support further clinical development of VCN-01 with immune checkpoint inhibitors or other immune modulating anticancer therapies in HNSCC and potentially other cancer indications.
Second Quarter Ended June 30, 2026 Financial Results

General and Administrative Expenses

General and administrative expenses decreased to $2.0 million for the three months ended June 30, 2026, from $11.2 million for the three months ended June 30, 2025. This decrease of 82% is primarily comprised of the prior year increase in fair value of the contingent consideration adjustment of $9.2 million due to the VIRAGE Phase 2b clinical trial of VCN-01 in PDAC achieving its primary survival and safety endpoints, offset set by current year increase in legal fees. The charge related to stock-based compensation expense was $110,000 for the three months ended June 30, 2026, compared to $97,000 for the three months ended June 30, 2025.

Research and Development Expenses

Research and development expenses decreased to $1.3 million for the three months ended June 30, 2026, from $2.0 million for the three months ended June 30, 2025. This decrease of 35% is primarily the result of lower indirect cost related to compensation expense and lower direct clinical trial expenses related to the Company’s Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients and lower expenses related to SYN-020, offset by higher direct expenses related to VCN-01 manufacturing activities and expenses associated with the planning for the Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period.

Other Income/Expense

Other income was $78,000 for the three months ended June 30, 2026, compared to other income of $74,000 for the three months ended June 30, 2025. Other income for the three months ended June 30, 2026 is comprised of interest income of $79,000 and an exchange loss of $1,000. Other income for the three months ended June 30, 2025 is comprised of interest income of $54,000 and an exchange gain of $20,000.

Cash and Cash Equivalents

Cash and cash equivalents totaled $11.3 million as of June 30, 2026, a decrease of $1.7 million from December 31, 2025. During the year ended December 31, 2025 and the quarter ended June 30, 2026, the primary use of cash was for working capital requirements and operating activities, which resulted in a net loss of $23.7 million and $5.3 million for the year ended December 31, 2025 and the six months ended June 30, 2026, respectively.

(Press release, Theriva Biologics, AUG 11, 2026, View Source [SID1234669964])

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

On August 11, 2026 NeOnc Technologies (NASDAQ:NTHI) reported it is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near its 52-week low, a relatively small trading float, more than 500,000 shares reported short, three Wall Street Buy ratings and a long-awaited brain-cancer data readout.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The question is whether the clinical data can justify the attention.

NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company says management will discuss efficacy and safety observations as well as planned regulatory next steps. The trial is fully enrolled.

For a stock recently trading around $3.50, the timing is significant.

A Stock Near the Bottom of Its Range

NTHI’s recent trading level is close to its approximately $3.01 52-week low, versus a $12.99 52-week high. Finviz currently shows the shares roughly 74% below that high and only modestly above the yearly low.

Wednesday’s data could provide the next major catalyst.

Unlike an earnings release or routine corporate update, a Phase 2a readout can directly change investors’ expectations for a drug’s clinical and commercial prospects. In NeOnc’s case, the readout concerns a program the company has already positioned as a central part of its development strategy.

NeOnc previously reported encouraging historical observations for NEO100, including a 24% radiographic remission rate in an expanded 25-patient cohort, 44% six-month progression-free survival, and 36% of patients alive at least 18 months after treatment initiation. Those figures are from earlier company-reported experience and should not be confused with Wednesday’s prospective Phase 2a topline results.

The Reported Float Is Small

The share structure adds another layer to the setup.

Finviz currently lists approximately 2.06 million shares in the public float, against roughly 24.13 million shares outstanding. It also reports approximately 520,000 shares short, a 25.33% short-float figure, and average volume of roughly 97,590 shares.

Other market-data providers calculate the float differently. StockAnalysis, for example, currently estimates a float of approximately 9.05 million shares, which would put the same 521,841-share short position at about 5.77% of float.

Regardless, that is more than half a million shares are reported short in a stock whose normal trading volume is relatively limited, so the short position represents over the highly sought-after 5 days to cover threshold.

If clinical results bring substantially more volume into NTHI, both short covering and new buyers could become meaningful sources of demand. That does not guarantee a squeeze or a higher share price, but it creates the potential for unusually fast price discovery.

Wall Street Is Already Looking Much Higher

NeOnc also enters the event with unusually wide analyst expectations relative to its recent share price.

Three firms currently carry Buy ratings:

Maxim Group — $20 price target
BTIG — $15 price target
Alliance Global Partners — $13 price target

The simple average is $16 per share.

Against a roughly $3.50 stock price, those targets represent a substantial valuation gap. Maxim’s $20 target is nearly six times that level, while the $13 target from Alliance Global Partners is still several multiples higher.

Those are analyst expectations, not guarantees, and Wednesday’s data could strengthen, weaken or completely change the assumptions supporting those targets.

There is another potentially important ownership detail. NeOnc’s latest available market-data estimates put insider ownership at roughly 55%, while institutional ownership is estimated at about 6.6%. The company has also disclosed insider buying, including a purchase of more than $500,000 of NTHI shares by CEO Amir Heshmatpour referenced in its first-quarter update.

Biotech Traders Have Seen How Fast Good Data Can Move a Stock

The broader biotech market has provided recent reminders that clinical data can radically change a company’s valuation in a single session.

Tango Therapeutics (NASDAQ:TNGX) surged after reporting initial Phase 1/2 data showing a 92% objective response rate among response-evaluable pancreatic-cancer patients treated with vopimetostat plus daraxonrasib. Six-month progression-free survival was 90%, and disease control reached 100% in the reported pancreatic-cancer cohort. Tango’s shares jumped approximately 53% that day, closing at $30.93.

The comparison is not a prediction for NTHI. The studies, drugs, patient populations and clinical-stage risks are different.

But the market reaction illustrates the mechanism: when clinical results materially exceed expectations, investors can rapidly reassess an entire company’s opportunity.

Intensity Therapeutics (NASDAQ:INTS) offers an even more dramatic example. Following positive Phase 1/2 data for INT230-6 in advanced cancers, the stock rose approximately 394% in a single session, from about $0.27 to $1.32, according to Genetic Engineering & Biotechnology News. The data showed a 75% disease-control rate among 64 patients and median overall survival of 11.9 months.

Again, those outcomes do not establish what NTHI will do.

They demonstrate why small biotechnology companies can become extremely volatile when meaningful clinical data arrives against a limited share supply.

Wednesday Is the Inflection Point

That leaves NTHI approaching the August 12 readout with several forces already in place:

A stock near its 52-week low.

A reported public float that varies significantly by data provider but is small under some methodologies.

521,841 shares reported short as of July 15.

Three Buy ratings with $13, $15 and $20 targets.

A fully enrolled Phase 2a brain-cancer trial.

And a scheduled topline data presentation Wednesday morning.

The bullish case is straightforward: compelling efficacy and safety data could force investors to reassess the value of NEO100 and the company’s broader CNS pipeline. A stronger-than-expected regulatory path could add another layer to that repricing.

The bearish case is equally straightforward: disappointing efficacy, safety concerns, ambiguous results or an uncertain regulatory path could overwhelm the technical setup. A low float can amplify selling just as easily as buying.

That is ultimately what makes Wednesday important.

The question isn’t whether NTHI has the ingredients for volatility. It clearly does.

The question is whether the NEO100 Phase 2a data are strong enough to change the fundamental story.

If they are, the market will have to determine how much that new information is worth.

And with NTHI trading near the bottom of its 52-week range, analyst targets extending as high as $20 and more than half a million shares reported short, that repricing could be anything but quiet.

The Catalyst

NeOnc Technologies Holdings (NASDAQ:NTHI)
NEO100-01 Phase 2a topline data presentation
Wednesday, August 12, 2026
8:30 a.m. ET / 5:30 a.m. PT

NeOnc says management will present topline efficacy and safety observations, discuss planned regulatory next steps and conduct a question-and-answer session.

Live webcast: View Source

Investor relations: View Source

A replay is expected to be available following the presentation.

(Press release, Neonc, AUG 11, 2026, View Source [SID1234669980])